Edgar Filing: Perlin Jonathan B - Form 4

Perlin Jonathan B Form 4 Image: Second Content of											
(Print or Type Responses)											
H			Symbol	2. Issuer Name and Ticker or Trading Symbol				5. Relationship of Reporting Person(s) to Issuer			
			HCA Healthcare, Inc. [HCA]					(Check all applicable)			
(Mon				. Date of Earliest Transaction Month/Day/Year) 2/22/2018				Director 10% Owner X Officer (give title Other (specify below) below) Pres-Clinical Services & CMO			
				mendment, Date Original Month/Day/Year)				6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting Person			
(City)	r cisoli										
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	ransaction Date 2A. Deemed				ties Ac	quired (A) (D)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s)	6. 7. Nature of Ownership Indirect Form: Beneficial Direct (D) Ownership or Indirect (Instr. 4) (I) (Instr. 4)		
Common				Code V	Amount	(D)	Price	(Instr. 3 and 4)			
Stock	02/22/2018			A <u>(1)</u>	19,200	А	\$0	100,497.6115	D		
Common Stock	02/22/2018			F	7,556	D	\$ 100.54	92,941.6115	D		
Common Stock	02/25/2018			М	3,452	А	<u>(2)</u>	96,393.6115	D		
Common Stock	02/25/2018			F	1,278	D	\$ 100.84	95,115.6115	D		
Common Stock								913	Ι	By 2011 GRAT, Reporting	

Edgar Filing: Perlin Jonathan B - Form 4

								Perso Trust			
Common Stock						3,846	I	By 20 GRA Repo Perso Trust	T, orting on		
Reminder: Report	t on a separate	e line for each class of						f 0EC 147			
			ii r d	nformatior equired to	n contain respond	ned in thi d unless	e collection of is form are no the form MB control				
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)											
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	 4. 5. Number of TransactionDerivative Code Securities (Instr. 8) Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) 		ve es d (A) or d of (D)	Expiration Date		7. Title and Amo Underlying Secu (Instr. 3 and 4)		
				Code V	(A)	(D)	Date Exercisable	Expiration Date	Title	Ar or Nu of Sh	
Stock Appreciation Right	\$ 47.97	02/22/2018		А	5,625		02/22/2018	02/05/2024	Common Stock	5	
Restricted Stock Units	<u>(2)</u>	02/25/2018		М		1,550	(4)	02/25/2025	Common Stock	1	
Restricted Stock Units	<u>(2)</u>	02/25/2018		М		1,902	(5)	02/25/2026	Common Stock	1	
Reporting Owners											

Reporting Owner Name / Address	Relationships						
F8	Director	10% Owner	Officer	Other			
Perlin Jonathan B							
ONE PARK PLAZA			Pres-Clinical Services & CMO				
NASHVILLE, TN 37203							

Signatures

/s/ Natalie Harrison Cline, Attorney-in-Fact

02/26/2018

**Signature of Reporting Person

Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

On February 4, 2015, the reporting person was granted 9,600 performance share units. The performance share units were eligible to vest based on achievement of a cumulative earnings per share goal for fiscal years 2015-2017. The number of performance share units that

- (1) were eligible to vest varied from zero (for actual performance less than 80% of target) to two times the units granted (for actual performance of 120% or more of target). Based upon the Company's achievement with respect to cumulative 2015-2017 earnings per share, the number of performance share units that vested equaled two times the units granted.
- (2) Restricted stock units convert into common stock on a one-for-one basis.

On February 5, 2014, the reporting person was granted 37,500 stock appreciation rights. The stock appreciation rights were eligible to vest in equal increments of up to 25% at the end of fiscal years 2014, 2015, 2016 and 2017 based upon the extent to which certain

- (3) EBITDA performance targets have been met for the applicable fiscal year. Based upon the Company's achievement with respect to the EBITDA performance criteria for 2017, 60% of the stock appreciation rights subject to such criteria vested, resulting in the vesting of 5,625 stock appreciation rights.
- (4) On February 25, 2015, the reporting person was granted 3,100 restricted stock units, vesting in two equal annual installments beginning on the second anniversary of the grant date.
- (5) On February 25, 2016, the reporting person was granted 3,805 restricted stock units, vesting in two equal annual installments beginning on the second anniversary of the grant date.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.